Table 1.
Baseline demographics of the experimental cohort partitioned by treatment group.
| Parameter | Treatment group | Mean + SD |
|---|---|---|
| Age (y) | Placebo | 20.8 ± 1.8 |
| 50 mg | 21.2 ± 2.3 | |
| 200 mg | 21.7 ± 2.4 | |
|
| ||
| Stature (cm) | Placebo | 170.6 ± 8.2 |
| 50 mg | 173.7 ± 9.3 | |
| 200 mg | 169.2 ± 9.9 | |
|
| ||
| Weight (kg) | Placebo | 69.8 ± 11.3 |
| 50 mg | 73.2 ± 14.9 | |
| 200 mg | 66.9 ± 14.6 | |
|
| ||
| Body mass index (kg·m−2) | Placebo | 23.9 ± 2.6 |
| 50 mg | 24.1 ± 3.4 | |
| 200 mg | 23.1 ± 3.1 | |
|
| ||
| Systolic blood pressure (mmHg) | Placebo | 116.9 ± 7.3 |
| 50 mg | 115.7 ± 7.5 | |
| 200 mg | 118.3 ± 6.0 | |
|
| ||
| Diastolic blood pressure (mmHg) | Placebo | 74.6 ± 6.6 |
| 50 mg | 71.4 ± 8.3 | |
| 200 mg | 77.8 ± 6.6 | |
|
| ||
| Resting HR (beats·min−1) | Placebo | 73.7 ± 8.4 |
| 50 mg | 74.8 ± 7.5 | |
| 200 mg | 74.9 ± 10.4 | |
|
| ||
| Maximal oxygen consumption (mL·kg·min−1) | Placebo | 41.6 ± 6.0 |
| 50 mg | 43.7 ± 7.1 | |
| 200 mg | 44.1 ± 7.6 | |
Sample size per group: PLA, 21; 50 mg, 19; 200 mg, 19.